glp-1 heart failure reduced ejection fraction Frontiers Effects of Glucagon-Like Peptide 1

10.1093/jpp/rgad014 136 ZhangY.TangC.HeY.ZhangY.LiQ.ZhangT.et al (2024)

HWR reports receiving research support for clinical trials, service as principal investigator, on advisory boards, speaking and consulting from Eli Lilly and Co, Esperion, Bayer, Boehringer Ingelheim, Novo Nordisk, Sanofi, and Zealand

In addition to aforementioned properties of GLP-1 agonists, it can also reduce hypertension by activating and phosphorylating endothelial nitric oxide synthase pathways, thus increasing the bioavailability of nitric oxide which promotes vasodilation

doi:10.1016/j.bcp.2020.114187 9

Attachment insecurity and anxiety-related avoidance can affect health behavior through reduced self-efficacy and difficulties in emotional regulation [122]